Cancer drugs **shortages** can be mitigated through an **early detection** system based on data **transparency.**

Cancer Drugs Shortages in Romania: Magnitude, causes and solutions

Mixich Vlad*, Voinea Ştefan**, Mardale Sânziana** * Cluj School of Public Health Babes-Bolyai University, Romania ** Romanian Health Observatory

OBJECTIVES

Cancer drugs shortages have a significant impact on patient access to essential treatment. Our study shows the extent of cancer drugs shortages in Romania during 2015-2017 and analyses for the first time its causes. We propose a framework which can be used for early detection of cancer drugs at high risk of shortage.

METHODS

Available administrative data for 113 INNs, corresponding to 534 products, from the National Oncology Program were analyzed in terms of availability on the market, price status and parallel trade status. In addition, 2683 complains of shortages filled in by patients and HCP during 2015-2017 were analyzed. Analysis was performed separately for each

pharmaceutical product and generic alternatives were included.

RESULTS


From the cancer medicines analyzed, 23 products were temporary unavailable on the Romanian market, 16 had their market authorization withdrawn by the MaH, 39 were at least once parallel traded, 16 products were more expensive than in the referenced EU countries thus not complying with the national regulations on external reference pricing, and 1 was registered with manufacturing difficulties. Results at INN level are visually represented below. By applying the decision tree developed, 13 cancer drugs were identified as having a high shortage risk. Shortage risk causes were identified, with the biggest preponderance being parallel trade, followed by pricing and regulatory policies, manufacturers' commercial interest and manufacturing difficulties.

CONCLUSION

Cancer drugs status should be continuously monitored to identify those with a high shortage risk and to enable early mitigation actions of the highly negative impact on patients. Policy tools and frameworks can be developed to implement proactive mechanisms if data on parallel trade, available stocks at regional level, discontinuation notifications from MaH and shortages notifications from patients/HCP are available in a transparent way.








Causes of the risk of shortages for cancer

Early detection of cancer drugs at high shortage risk



CANCER DRUG
Mercentower (M)
Branch Rower (M)
Mercentower (M)
Branch Rower (M)
Mercentower (M)
Mercentower



Take a picture to download the full report in Romanian



Cancer drugs for which shortages were reported